1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Diagnostics and Therapeutics for Autism Spectrum Disorders: Global Markets

REPORT HIGHLIGHTS

The global autism spectrum disorders (ASD) market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%.

This report provides:

An overview of the regional and global markets for Autism Spectrum Disorder (ASD) therapies and diagnostics.
Analyses of global market trends, with data from 2013, 2014, and projections of compound annual growth rates (CAGRs) through 2019.
An overview of ASDs including types, epidemiology, symptoms, and causes and pathophysiology.
Coverage of approved therapies and tolerated off-label alternative treatments for ASD.
In-depth analysis of the ASD therapies market dynamics, specifically growth drivers, inhibitors, and opportunities.
A relevant patent analysis including patents nearing expiration, and recently issued patents.
Comprehensive profiles of major players in the field.

SCOPE OF THE STUDY

The scope of this study encompasses the global and regional markets for therapeutic and diagnostic technologies of ASD. BCC Research analyzed each market and its applications, regulatory environment, technology, market projections and market share. Issues discussed include the major drug profiles, technological features and trends. The global markets for the ASD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Spain, Italy and Japan. The markets of the rest of the world are not reported due to their economic insignificance for this report.

Table Of Contents

Diagnostics and Therapeutics for Autism Spectrum Disorders: Global Markets

Chapter - 1: Introduction - Complimentary 3

STUDY OBJECTIVES
REASONS FOR DOING THE STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
INFORMATION SOURCES AND TECHNOLOGY BENCHMARKING
FORECASTING METHODOLOGY
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER

Chapter - 2: SUMMARY 4

Table Summary : GLOBAL ASD MARKET, THROUGH 2019
Figure Summary : GLOBAL ASD MARKET, 2013-2019

Chapter - 3: OVERVIEW 13

DEFINITION OF AUTISM
BACKGROUND OF AUTISM
WHY IS AUTISM A 'SPECTRUM' DISORDER?
CORE SYMPTOMS OF ASD
NON-CORE SYMPTOMS OF ASD
ETIOLOGY OF ASD
EPIDEMIOLOGY OF ASD
STANDARDS FOR THE DIAGNOSIS AND TREATMENT OF ASD
PHARMACEUTICAL TREATMENT OF ASD

Chapter - 4: REGULATORY LANDSCAPE 5

Table 2 : LIST OF PEDIATRIC LABEL REVISIONS FOR APPROVED AND OFF-LABEL DRUGS USED ON ASD POPULATIONS
Table 3 : LIST OF ISSUED SAFETY WARNINGS FOR APPROVED AND OFF-LABEL PHARMACEUTICALS USED ON ASD POPULATIONS
Table 4 : LIST OF DRUGS UNDER PEDIATRIC INVESTIGATION

Chapter - 5: GLOBAL MARKETS 46

THERAPEUTICS MARKET
GLOBAL ASD DIAGNOSTICS MARKET
GLOBAL ASD MARKET DRIVERS AND RESTRAINTS
Table 5 : GLOBAL ASD MARKET BY APPLICATION, THROUGH 2019
Figure 1 : GLOBAL ASD MARKET BY APPLICATION, 2013-2019

Chapter - 6: MARKETS IN NORTH AMERICA 22

THERAPEUTICS MARKET
NORTH AMERICAN ASD DIAGNOSTICS MARKETS
NORTH AMERICAN ASD MARKET BY COUNTRY
Figure 34 : ASD PREVALENCE RATES IN NORTH AMERICA, 2000-2013
Table 37 : NORTH AMERICAN ASD MARKET BY APPLICATION, THROUGH 2019
Figure 35 : NORTH AMERICAN ASD MARKET BY APPLICATION, 2013-2019

Chapter - 7: MARKETS IN EUROPE 20

THERAPEUTICS MARKET
EU5 ASD DIAGNOSTICS MARKETS
EU5 ASD MARKET BY COUNTRY
Figure 48 : ASD COMBINED PREVALENCE RATES IN EU5 COUNTRIES, 2000 TO 2011
Table 50 : EU5 ASD MARKET BY APPLICATION, THROUGH 2019
Figure 49 : EU5 ASD MARKET BY APPLICATION, 2013-2019

Chapter - 8: MARKETS IN JAPAN 14

THERAPEUTICS MARKET
JAPANESE ASD DIAGNOSTICS MARKET
Figure 61 : ASD PREVALENCE RATES IN JAPAN, 2000-2013
Table 62 : JAPANESE ASD MARKET BY APPLICATION, THROUGH 2019
Figure 62 : JAPANESE ASD MARKET BY APPLICATION, 2013-2019

Chapter - 9: PIPELINE ASSESSMENT 15

OVERVIEW
STRATEGIC PIPELINE ASSESSMENT
PIPELINE ANALYSIS BY PHASE OF DEVELOPMENT
PIPELINE BY MECHANISM OF ACTION
CLINICAL PIPELINE BY INDICATION
CLINICAL PIPELINE BY PHENOTYPES OF ASD
TECHNOLOGICAL TRENDS AND ANALYTICAL FRAMEWORK
MOST PROSPECTIVE DRUG PROFILES

Chapter - 10: DIAGNOSTIC TECHNOLOGIES: RECENT DEVELOPMENTS 9

MARKET-ENTRY PRODUCTS
COMPARATIVE EVALUATION FOR MARKET-ENTRY PRODUCTS
IN THE PIPELINE

Chapter - 11: COMPANY PROFILES 11

THERAPEUTICS
DIAGNOSTICS

List of Tables

Summary Table : GLOBAL ASD MARKET, THROUGH 2019
Table 1 : ASD-ASSOCIATED COMORBIDITIES AND THEIR PREVALENCE RATES
Table 2 : LIST OF PEDIATRIC LABEL REVISIONS FOR APPROVED AND OFF-LABEL DRUGS USED ON ASD POPULATIONS
Table 3 : LIST OF ISSUED SAFETY WARNINGS FOR APPROVED AND OFF-LABEL PHARMACEUTICALS USED ON ASD POPULATIONS
Table 4 : LIST OF DRUGS UNDER PEDIATRIC INVESTIGATION
Table 5 : GLOBAL ASD MARKET BY APPLICATION, THROUGH 2019
Table 6 : GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, THROUGH 2019
Table 7 : GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019
Table 8 : GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 9 : GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 10 : GLOBAL ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 11 : GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 12 : GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 13 : GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 14 : GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 15 : GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 16 : GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, THROUGH 2019
Table 17 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, THROUGH 2019
Table 18 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, THROUGH 2019
Table 19 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, THROUGH 2019
Table 20 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, THROUGH 2019
Table 21 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, THROUGH 2019
Table 22 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, THROUGH 2019
Table 23 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, THROUGH 2019
Table 24 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), THROUGH 2019
Table 25 : GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, THROUGH 2019
Table 26 : GLOBAL ASD THERAPEUTICS MARKET FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, THROUGH 2019
Table 27 : GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2019
Table 28 : GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, THROUGH 2019
Table 29 : GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, THROUGH 2019
Table 30 : GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, THROUGH 2019
Table 31 : GLOBAL ASD DIAGNOSTICS MARKET, THROUGH 2019
Table 32 : GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, THROUGH 2019
Table 33 : GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, THROUGH 2019
Table 34 : GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, THROUGH 2019
Table 35 : GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, THROUGH 2019
Table 36 : GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, THROUGH 2019
Table 37 : NORTH AMERICAN ASD MARKET BY APPLICATION, THROUGH 2019
Table 38 : NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019
Table 39 : NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019
Table 40 : NORTH AMERICAN ANTIPSYCHOTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 41 : NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 42 : NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 43 : NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 44 : NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 45 : NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 46 : NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 47 : NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 48 : NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019
Table 49 : NORTH AMERICAN ASD MARKET BY COUNTRY, THROUGH 2019
Table 50 : EU5 ASD MARKET BY APPLICATION, THROUGH 2019
Table 51 : EU5 ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019
Table 52 : EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019
Table 53 : EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 54 : EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 55 : EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 56 : EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 57 : EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 58 : EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 59 : EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019
Table 60 : EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019
Table 61 : EU5 ASD MARKETS BY COUNTRY, THROUGH 2019
Table 62 : JAPANESE ASD MARKET BY APPLICATION, THROUGH 2019
Table 63 : JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019
Table 64 : JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 65 : JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 66 : JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 67 : JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 68 : JAPANESE ANTIHYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 69 : JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 70 : JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019
Table 71 : JAPANESE ASD DIAGNOSTICS MARKET, THROUGH 2019
Table 72 : NUMBER OF PHASE III CLINICAL TRIALS BY COUNTRY, 2014
Table 73 : NUMBER OF PHASE II CLINICAL TRIALS BY COUNTRY, 2014
Table 74 : NUMBER OF PHASE I CLINICAL TRIALS BY COUNTRY, 2014
Table 75 : NUMBER OF CLINICAL TRIALS BY MECHANISM OF ACTION, 2014
Table 76 : NUMBER OF CLINICAL TRIALS BY INDICATION, 2014
Table 77 : NUMBER OF CLINICAL TRIALS BY PHENOTYPES OF ASD BY COUNTRY, 2014
Table 78 : TARGET DRUG PROFILE: NNZ-2566
Table 79 : TARGET DRUG PROFILE: CM-AT
Table 80 : TARGET DRUG PROFILE: RG7314
Table 81 : TARGET DRUG PROFILE: LATUDA
Table 82 : MARKET VALUE ESTIMATES OF FOUR MARKET-ENTRY ASD DIAGNOSTIC PRODUCTS
List of Figures
Summary Figure : GLOBAL ASD MARKET, 2013-2019
Figure 1 : GLOBAL ASD MARKET BY APPLICATION, 2013-2019
Figure 2 : GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, 2013-2019
Figure 3 : GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019
Figure 4 : GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019
Figure 5 : GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019
Figure 6 : GLOBAL ANTIDEPRESSANTS MARKET FOR ASD POPULATIONS, 2013-2019
Figure 7 : GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019
Figure 8 : GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019
Figure 9 : GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019
Figure 10 : GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019
Figure 11 : GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, 2013-2019
Figure 12 : GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, 2013-2019
Figure 13 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, 2013-2019
Figure 14 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, 2013-2019
Figure 15 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, 2013-2019
Figure 16 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, 2013-2019
Figure 17 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, 2013-2019
Figure 18 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, 2013-2019
Figure 19 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, 2013-2019
Figure 20 : GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), 2013-2019
Figure 21 : GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, 2013-2019
Figure 22 : GLOBAL ASD THERAPEUTICS FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, 2013-2019
Figure 23 : GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2013-2019
Figure 24 : GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, 2013-2019
Figure 25 : GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, 2013-2019
Figure 26 : GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, 2013-2019
Figure 27 : GLOBAL ASD THERAPEUTICS MARKET BY COMPANY, FOR 2014
Figure 28 : GLOBAL ASD DIAGNOSTICS MARKET, 2013-2019
Figure 29 : GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, 2013-2019
Figure 30 : GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, 2013-2019
Figure 31 : GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, 2013-2019
Figure 32 : GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, 2013-2019
Figure 33 : GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, 2013-2019
Figure 34 : ASD PREVALENCE RATES IN NORTH AMERICA, 2000-2013
Figure 35 : NORTH AMERICAN ASD MARKET BY APPLICATION, 2013-2019
Figure 36 : NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019
Figure 37 : NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019
Figure 38 : NORTH AMERICAN ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 39 : NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 40 : NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 41 : NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 42 : NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 43 : NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 44 : NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 45 : NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 46 : NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019
Figure 47 : NORTH AMERICAN ASD MARKET BY COUNTRY, 2013-2019
Figure 48 : ASD COMBINED PREVALENCE RATES IN EU5 COUNTRIES, 2000 TO 2011
Figure 49 : EU5 ASD MARKET BY APPLICATION, 2013-2019
Figure 50 : EU5 ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019
Figure 51 : EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019
Figure 52 : EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 53 : EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 54 : EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 55 : EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 56 : EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 57 : EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 58 : EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019
Figure 59 : EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019
Figure 60 : EU5 ASD MARKETS BY COUNTRY, 2013-2019
Figure 61 : ASD PREVALENCE RATES IN JAPAN, 2000-2013
Figure 62 : JAPANESE ASD MARKET BY APPLICATION, 2013-2019
Figure 63 : JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019
Figure 64 : JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019
Figure 65 : JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019
Figure 66 : JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, 2013-2019
Figure 67 : JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019
Figure 68 : JAPANESE ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019
Figure 69 : JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019
Figure 70 : JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019
Figure 71 : JAPANESE ASD DIAGNOSTICS MARKET, 2013-2019

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...

Epiomic Epidemiology Series: Traumatic Brain Injury Forecast in 21 Major Markets 2016-2026

Epiomic Epidemiology Series: Traumatic Brain Injury Forecast in 21 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Traumatic Brain Injury in 21 Major Markets Traumatic brain injury (TBI) or acquired brain injury is a non-specific term describing ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.